Patent intelligence · US
US 11260120
Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
Patent details — US 11260120
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 1, 2022
- Expiration
- Feb 24, 2042
- Applicant
- INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
- Claims
- 44
- CPC classes
- A61K, A61K2039/53, A61K2039/55505, A61K2039/70
Quick answer
US 11260120 (Immunogenic composition comprising a fusion peptide derived from superantigen toxoids) is held by INTEGRATED BIOTHERAPEUTIC VACCINES, INC.. Status: granted. Granted Mar 1, 2022. Expires Feb 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
- Grant date
- Expiration
- Claims
- 44
- CPC classes
- A61K, A61K2039/53, A61K2039/55505, A61K2039/70, A61K39/085, A61P
More from INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12076377
Variant sulfatase enzymes with enhanced properties
granted -
US 11421021
Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
granted -
US 11186626
Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
granted -
US 11154614
Method for producing virus like particles
granted -
US 11135280
Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
granted -
US 11028153
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
granted -
US 10653800
Oligonucleotide-based probes for detection of bacterial nucleases
granted
Frequently asked questions
What is US patent 11260120?
US 11260120 (Immunogenic composition comprising a fusion peptide derived from superantigen toxoids) is held by INTEGRATED BIOTHERAPEUTIC VACCINES, INC.. Status: granted. Granted Mar 1, 2022. Expires Feb 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11260120?
INTEGRATED BIOTHERAPEUTIC VACCINES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 42 pharmaceutical patents for this assignee.
When does US 11260120 expire?
Our index shows an expiration date of Feb 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.